title: Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.
abstract: Assays of human postmortem brain tissue have revealed that smokers have greater densities of high-affinity nicotinic acetylcholine receptors (nAChRs) in several brain regions than do nonsmokers or exsmokers. Quantitative PET imaging of nAChRs in humans has recently been reported using the alpha4beta2* subtype-specific radioligand 2-(18)F-FA-85380 (2FA).
  
  
  METHODS
  We used PET and 2FA to measure total volumes of distribution corrected for the free fraction of 2FA in plasma (V(T)/f(P)) in 10 nonsmokers and 6 heavy smokers (>14 cigarettes/d; abstinent for >36 h). Dynamic PET scans were performed over 8 h, commencing immediately after a bolus injection of 2FA. Anatomic sampling was performed on PET images that were coregistered to MR images acquired from each volunteer. Data were analyzed by Logan plots and by 1- and 2-tissue-compartment models using unbound, unmetabolized arterial 2FA concentration as the input function.
  
  
  RESULTS
  All modeling methods yielded similar results. V(T)/f(P) was significantly higher in smokers than in nonsmokers in all brain regions tested, except the thalamus. We used measures of V(T)/f(P) and estimates of nondisplaceable volume of distribution and found 25%-200% higher values in smokers than in nonsmokers for the volume of distribution for the specific binding compartment in the frontal cortex, midbrain, putamen, pons, cerebellum, and corpus callosum. These findings were consistent with voxel-based analysis using statistical parametric mapping.
  
  
  CONCLUSIONS
  Our findings suggest that PET with 2FA can be used to study the role of nicotine-induced upregulation of nAChRs in active smokers and during smoking cessation.
authors.affiliation: National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland, USA.
authors.forename: Alexey G
authors.initials: AG
authors.lastname: Mukhin
authors.forename: Alane S
authors.initials: AS
authors.lastname: Kimes
authors.forename: Svetlana I
authors.initials: SI
authors.lastname: Chefer
authors.forename: John A
authors.initials: JA
authors.lastname: Matochik
authors.forename: Carlo S
authors.initials: CS
authors.lastname: Contoreggi
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Horti
authors.forename: D Bruce
authors.initials: DB
authors.lastname: Vaupel
authors.forename: Olga
authors.initials: O
authors.lastname: Pavlova
authors.forename: Elliot A
authors.initials: EA
authors.lastname: Stein
mesh_terms: D000328:Adult; D001384:Azetidines; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000295:instrumentation* / Q000379:methods*; D011725:Pyridines; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic / Q000096:biosynthesis*; D015203:Reproducibility of Results; D012907:Smoking; D013997:Time Factors
chemical_list: C119803:2-fluoro-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D011725:Pyridines; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; D009538:Nicotine
references.citation: MMWR Morb Mortal Wkly Rep. 2002 Apr 12;51(14):300-3
references.pmid: 12002168
references.citation: Pharmacol Biochem Behav. 1987 Jul;27(3):505-12
references.pmid: 2821553
references.citation: Psychopharmacology (Berl). 1999 Nov;147(1):25-6
references.pmid: 10591862
references.citation: J Nucl Med. 2007 Nov;48(11):1829-35
references.pmid: 17942810
references.citation: FASEB J. 2003 Jul;17(10):1331-3
references.pmid: 12759330
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):907-15
references.pmid: 16894067
references.citation: J Subst Abuse. 1989;1(3):273-86
references.pmid: 7580219
references.citation: J Neurosci. 2006 Aug 23;26(34):8707-14
references.pmid: 16928859
references.citation: Clin Pharmacol Ther. 1982 Dec;32(6):758-64
references.pmid: 7140139
references.citation: Neuroimage. 2008 Jan 15;39(2):717-27
references.pmid: 17962044
references.citation: J Pharmacol Exp Ther. 1985 Dec;235(3):619-28
references.pmid: 4078726
references.citation: J Pharmacol Exp Ther. 1997 Jul;282(1):7-13
references.pmid: 9223534
references.citation: Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1620-9
references.pmid: 14523584
references.citation: J Nucl Med. 2000 Sep;41(9):1552-60
references.pmid: 10994738
references.citation: Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):183-90
references.pmid: 11926380
references.citation: Synapse. 2003 Apr;48(1):25-34
references.pmid: 12557269
references.citation: Trends Pharmacol Sci. 1990 Jun;11(6):216-9
references.pmid: 2200178
references.citation: Nucl Med Biol. 2007 Feb;34(2):221-8
references.pmid: 17307130
references.citation: Mol Pharmacol. 2000 Mar;57(3):642-9
references.pmid: 10692507
references.citation: Neuroscience. 1998 Nov;87(1):63-78
references.pmid: 9722142
references.citation: J Pharmacol Exp Ther. 1991 Sep;258(3):1127-36
references.pmid: 1890617
references.citation: J Nucl Med. 2005 Feb;46(2):240-7
references.pmid: 15695782
references.citation: Science. 2004 Nov 5;306(5698):1029-32
references.pmid: 15528443
references.citation: J Neurosci. 2003 Dec 17;23(37):11554-67
references.pmid: 14684858
references.citation: Nature. 2005 Jul 7;436(7047):103-7
references.pmid: 16001069
references.citation: J Neurosci. 2000 Sep 1;20(17):6431-41
references.pmid: 10964949
references.citation: Psychopharmacol Bull. 1973 Jan;9(1):13-28
references.pmid: 4682398
references.citation: Mol Pharmacol. 1994 Sep;46(3):523-30
references.pmid: 7935334
references.citation: Synapse. 2004 Sep 1;53(3):184-9
references.pmid: 15236351
references.citation: Clin Pharmacol Ther. 1993 Mar;53(3):316-23
references.pmid: 8453850
references.citation: J Nucl Med. 2003 Apr;44(4):596-601
references.pmid: 12679405
references.citation: Mol Pharmacol. 1997 Sep;52(3):524-34
references.pmid: 9281615
references.citation: Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8
references.pmid: 15050613
references.citation: Nucl Med Biol. 1998 Oct;25(7):599-603
references.pmid: 9804040
references.citation: J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
references.pmid: 17519979
references.citation: Neurosci Lett. 2008 Jan 3;430(1):34-7
references.pmid: 17997038